HIV Clinical Trial
Official title:
Motivating HIV+ Women: Risk Reduction and ART Adherence
The purpose of this study is to determine if a group motivational interviewing based intervention will increase adherence to antiretroviral medications and use of risk reduction behaviors.
Women are the fastest growing group of persons with AIDS. They are often diagnosed later in
the disease, when antiretroviral therapy (ART) is strongly indicated. Currently ART involves
the use of multiple medications that must be taken under strict conditions at regular time
intervals up to as many as 4 different times a day. Some medications must be taken on an
empty stomach, some with high fat food, some with low fat food, and all of these must be
coordinated throughout the day. It is extremely important for patients to take ART exactly
as prescribed and not miss any doses in order to reduce the amount of HIV virus in the
bloodstream, increase the CD4 cell counts, prevent the serious consequences of AIDS,
hospitalizations, and development of drug resistant strains. These regimen-related problems
and the high care-taking burden placed on HIV+ women for their children and partners make
near perfect adherence difficult to achieve. And, as women on ART begin to feel better and
resume their normal activities, including sexual activities, adherence to behaviors that
contribute to reducing the risk of spreading HIV (RRB), such as condom use and safe needle
use in injection drug users becomes crucial. Researches have shown that only about 11% to
63% of HIV+ women use condoms consistently.
The primary purpose of this randomized controlled behavioral trial is to test the effect of
a nurse led group motivational intervention for HIV+ women on adherence to ART and RRB. The
secondary purpose is to examine the mediator effect of 3 variables that have been shown to
be important in behavior change: self-efficacy, outcome expectancy, and personal goals. The
Motivational Group + Usual Care (MG+UC) intervention builds on the usual care provided at
the agencies and has Motivational Interviewing (MI) as a central component. It consists of 8
90 minute sessions, 1 week apart, led by a specially trained nurse, to motivate women to
adhere to both ART and RRB. The intervention will be compared to an 8 session health
promotion program (HPP+UC) that is led by a nurse health educator. These sessions will focus
on nutrition, exercise, stress management, and women's health issues. These sessions will
also be 90 minutes in length and meet weekly for 8 weeks. Both groups will receive beauty
and pampering incentives such as beauty makeovers, skin care instruction, and massages after
several of the sessions, as well as child care, transportation tokens, and monetary
incentives of $10 for attendance at each of the first 4 groups and $15 for attendance at
each of the last 4 groups. Snacks appropriate for ART and immune status will be supplied to
the MG+UC group, and fruits, vegetables, and other nutritious snacks will be provided to the
HPP+UC group. Groups will be held at AID Atlanta, the Infectious Disease Program of the
Grady Health System, and at the Infectious Disease Clinic of Emory Crawford Long.
In order to be eligible to participate, the women must be HIV+, over 18 years of age, be on
a new or different ART or have self-reported nonadherence to her current ART regimen, speak
and understand English, and be mentally stable as determined by a screening assessment. All
participants will complete a baseline assessment, and follow-up assessments immediately, 3,
6, and 9 months after the end of the group. Participants will be paid $25 for each
assessment. We expect 300 women to be randomized and participate; pregnant women will not be
excluded.
We hypothesize that the women who are randomized to the MG+UC group, will, on the immediate,
3, 6, and 9 month follow-up assessments have higher mean adherence rates to ART, report more
frequent use of RRB, have higher CD4 counts, and lower mean viral loads than those
randomized to the HPP+UC group. We also hypothesize that the effects of the intervention on
adherence to ART and RRB will be brought about by higher mean levels of self-efficacy, more
positive expected outcomes, and more specific and effective personal goals.
As noted above, MI forms the basis for the intervention. MI is a client-focused method of
counseling used to help clients deal with ambivalence about changing behavior. MI principles
include expressing empathy, developing discrepancy, rolling resistance, and supporting
self-efficacy. It has been used primarily with individuals, but some MI groups have been
described with substance users. Our application in a group format with HIV+ women is new and
innovative.
All participants will receive the usual care plus either the Health Promotion Program or the
Motivational Interviewing Intervention. How the usual care is administered varies by agency
but in general for ART consists of prescription of new or different ART regimen based on
established clinical criteria and guidelines by the Panel on Clinical Practices for
Treatment of HIV infection, education about the medications (including actions, side
effects, special requirements), setting up the medication schedule, and follow-up regarding
medication taking. The usual RRB education includes information about risk reduction
practices such as condom use, sexual practices, needle cleansing, and needle sharing.
Depending on the agency, the usual care may be formalized and administered by health care
providers, nurses, social workers, and/or health educators.
This innovative project is designed to promote adherence to both ART and RRB, something that
has not been described so far in the literature. Adherence to ART promotes health and
reduces infectiousness, including transmission of HIV from mother to fetus. Adherence to RRB
reduces the spread of HIV. Thus, if effective, the intervention will promote health of HIV+
women and reduce the spread of HIV.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |